Ofatumumab – B Cell Therapy
Ofatumumab Efficacy & Safety
[EPR-237] Longer-Term (up to 6 Years) Efficacy of Ofatumumab in Recently Diagnosed Treatment-Naive Relapsing Multiple Sclerosis
Gold R. et al
Remibrutinib – BTK inhibitor
Remibrutinib Safety
[EPR-232] Remibrutinib, a BTKi, has no Impact on Serum Immunoglobulin Levels: Insights From Chronic Spontaneous Urticaria
Airas L. et al
MS Portfolio
[EPR-221] First Assessment of sNfL Integration in Everyday Clinical Practice – Lessons From NeofiLos
Ziemssen T. et al
MLR ID - 441321